Greiner Bio-One, Inc. Announces the Creation of a New Patient-Derived Xenograft Model Using Magnetic 3D Cell Culture

Published: Jun 04, 2018

MONROE, N.C.--(BUSINESS WIRE)-- Greiner Bio-One North America Inc. is announcing the creation of a patient-derived xenograft model for inflammatory breast cancer (IBC) using magnetic 3D cell culture research methods that mimic the current patient-derived xenograft (PDX) model standard. This new and effective methodology will provide a more efficient method to combat one of the most aggressive forms of breast cancer.

3D Versus In Vivo

A significant drawback associated with PDX systems is that they require immense resources, are costly and time consuming, and offer limited use as a platform for high throughput screening. However, magnetic 3D bioprinting technology has now afforded development of a new method to utilize PDX-derived ex-vivo tumor tissue within high throughput drug screens.

The PDX-derived ex-vivo tumor tissue generated through magnetic 3D bioprinting mirrors the original PDX tumor in both tissue architecture and genetic signature. The predictive value of the screening template has been confirmed by demonstrating a similar response outcome between the template and a PDX mouse system generated from the same original tumor tissue and treated with the same panel of drugs. Utilizing an Inflammatory Breast Cancer PDX system as the model system, the ex-vivo tumor tissue template was screened with the anti-cancer drug library, resulting in the identification of 7 lead candidates that presented stronger anti-tumor activity compared to the standard of care agents used to treat IBC patients in the clinics.

Incorporating the ex-vivo tumor tissue high throughput screening platform as an early step in a PDX system will permit the identification of new and effective tumor specific therapies in a time, cost and resource efficient manner. For the full study that is published in PLOS ONE, visit:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195932.

Greiner Bio-One North America, Inc. is a privately held plastic manufacturing company located in Monroe, NC whose three divisions manufacture a variety of products for the medical and research fields. The manufactured products include plasticware for the cultivation and analysis of cell and tissue cultures, microplates for high-throughput screening related to drug screening, products for blood and specimen collection, tests for the detection of bacteria and viruses, as well as, custom-made products. As an international manufacturer with global reach, Greiner Bio-One provides the manufacturing, distribution logistics and product application support to the world’s largest hospitals, pharmaceutical and biotechnology corporations.

For more information about Greiner Bio-One North America, Inc. please visit http://www.gbo.com.

 

Contacts

Greiner Bio-One North America, Inc.
Mackenzie Farone-Waite, +1-704-261-7860
Mackenzie.Farone-Waite@gbo.com

 

 
 

Source: Greiner Bio-One North America, Inc.

Back to news